Literature DB >> 22941236

Impact of posttransplantation glomerulonephritis on long-term outcome of kidney transplants: single-center 20-year experience.

Tung-Min Yu1, Mei-Chin Wen, Ming-Ju Wu, Cheng-Hsu Chen, Chi-Hung Cheng, Chi-Yuan Li, Kuo-Hsiung Shu.   

Abstract

BACKGROUND: Successful renal transplantation has been performed in patients with end-stage renal disease and has been routine in patients with end-stage renal failure for more than two decades. Despite advances in the use of immunosuppressants, there has been only modest improvement in long-term allograft survival. Accumulating data have demonstrated that chronic rejection and recurrent glomerulonephritis are major causes of long-term allograft loss. However, data regarding the long-term impact of posttransplantation glomerulonephritis (PTGN) on ethnic Chinese populations are still unavailable.
METHODS: From 1984 to 2010, a total of 268 patients who underwent renal allograft biopsies were reviewed retrospectively. Renal outcomes were compared by Kaplan-Meier analysis, and risk factors for renal survival and all-cause mortality were analyzed using the Cox proportional hazards model.
RESULTS: In all, 85 patients (31.7%) had PTGN, and the mean time of disease onset was 5.32±5.18 years after transplantation. Among the 85 PTGN cases, 33 (39%) were immunoglobulin A (IgA) nephropathy, 24 (28%) were focal segmental glomerulosclerosis, and 8 (9.4%) were membranous GN. Significant risk was associated with posttransplant IgA GN in hepatitis B virus carriers (odds ratio 5.371, 95% confidence interval 1.68, 17.19; p=0.0064). A total of 45 PTGN patients had allograft loss, of whom 49% had IgA nephropathy. Patients with PTGN had inferior allograft survival rates compared to those with other pathologic findings (p<0.0003).
CONCLUSIONS: Taken together, our results indicate that PTGN had a strong negative impact on long-term kidney graft survival. Posttransplant IgA nephropathy is a leading cause of allograft loss in Chinese kidney transplant patients with PTGN.

Entities:  

Mesh:

Year:  2012        PMID: 22941236     DOI: 10.1007/s00268-012-1759-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  35 in total

1.  Experiences with renal homotransplantation in the human: report of nine cases.

Authors:  D M HUME; J P MERRILL; B F MILLER; G W THORN
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

Review 2.  Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.

Authors:  Harold Yang
Journal:  Am J Kidney Dis       Date:  2006-04       Impact factor: 8.860

Review 3.  Current and evolving immunosuppressive regimens in kidney transplantation.

Authors:  Robert S Gaston
Journal:  Am J Kidney Dis       Date:  2006-04       Impact factor: 8.860

Review 4.  Overcoming barriers to long-term graft survival.

Authors:  Bruce Kaplan
Journal:  Am J Kidney Dis       Date:  2006-04       Impact factor: 8.860

5.  Risk factors for late kidney allograft failure.

Authors:  Claudio Ponticelli; Margarita Villa; Bruno Cesana; Giuseppe Montagnino; Antonio Tarantino
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

6.  Recurrent IgA nephropathy in renal transplant allografts.

Authors:  A Y Wang; F M Lai; A W Yu; P K Lam; K M Chow; P C Choi; S F Lui; P K Li
Journal:  Am J Kidney Dis       Date:  2001-09       Impact factor: 8.860

7.  Kidney transplantation in patients with IgA mesangial glomerulonephritis.

Authors:  C Ponticelli; L Traversi; A Feliciani; B M Cesana; G Banfi; A Tarantino
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

8.  Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens.

Authors:  F M Lai; K N Lai; J S Tam; S F Lui; K F To; P K Li
Journal:  Am J Surg Pathol       Date:  1994-02       Impact factor: 6.394

9.  Racial disparities in renal allograft survival: a public health issue?

Authors:  Devin E Eckhoff; Carlton J Young; Robert S Gaston; Steven W Fineman; Mark H Deierhoi; Margaret T Foushee; Robert N Brown; Arnold G Diethelm
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

10.  Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.

Authors:  Tak Mao Chan; Guo Xiang Fang; Colin S o Tang; Ignatius K p Cheng; Kar Neng Lai; Stephen K n Ho
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

View more
  2 in total

1.  Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry.

Authors:  Wen-Ling Yang; Bhadran Bose; Lei Zhang; Megan Mcstea; Yeoungjee Cho; Magid Fahim; Carmel M Hawley; Elaine M Pascoe; David W Johnson
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

Review 2.  Recurrent Glomerulonephritis in the Kidney Allograft.

Authors:  Shane A Bobart; Mariam P Alexander; Andrew Bentall
Journal:  Indian J Nephrol       Date:  2020-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.